Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Vicriviroc (vye-kri-VYE-rock) is an investigational drug (not yet approved by Government
Regulatory Authorities for commercial use) that belongs to a new class of drugs, called CCR5
receptor blockers. This group of drugs blocks one of the ways HIV enters T-cells (the cells
that fight infection). Previous smaller studies in HIV treatment-experienced patients, have
shown that vicriviroc is safe and effective. The purpose of this study is to confirm the
previous findings in a larger phase 3 study over a 48-week period, and show that when taken
in combination with other appropriate HIV drugs, vicriviroc can decrease the level of HIV
(viral load) in the blood and that it is well tolerated.